Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.08T
Market cap1.08T
Price-Earnings ratio
40.36
Price-Earnings ratio40.36
Dividend yield
0.58%
Dividend yield0.58%
Average volume
2.45M
Average volume2.45M
High today
$1,216.94
High today$1,216.94
Low today
$1,136.74
Low today$1,136.74
Open price
$1,174.00
Open price$1,174.00
Volume
2.75M
Volume2.75M
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,149.20, giving the company a market capitalization of 1.08T. It carries a P/E multiple of 40.36 and pays a dividend yield of 0.58%.

On 2026-08-05, Eli Lilly(LLY) stock traded between a low of $1,136.74 and a high of $1,216.94. Shares are currently priced at $1,149.20, which is +1.1% above the low and -5.6% below the high.

The Eli Lilly(LLY)'s current trading volume is 2.75M, compared to an average daily volume of 2.45M.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,249.45 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,249.45 at its peak.

LLY News

Simply Wall St 17m
Eli Lilly Could Be 24% Below Fair Value As Revenue Outlook Rises

Eli Lilly (LLY) is back in focus after reporting second quarter 2026 results and lifting its full year revenue outlook to US$85b to US$87b, giving investors fre...

Eli Lilly Could Be 24% Below Fair Value As Revenue Outlook Rises
Investor's Business Daily 1h
Lilly's GLP-1 Drugs Just Blew Sales Expectations Out Of The Water - Investor's Business Daily

...

Lilly's GLP-1 Drugs Just Blew Sales Expectations Out Of The Water - Investor's Business Daily
24/7 Wall St. 2h
GLP-1's Drove Eli Lilly's Record-Breaking Q2, but AI Will Be Its Future

GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future By Rich Duprey Published Aug 5, 9:50AM EDT Quick Read Eli Lilly Q2 revenue surged 48%...

GLP-1's Drove Eli Lilly's Record-Breaking Q2, but AI Will Be Its Future

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

Investor's Business Daily 3h
Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop

Dow Jones Futures Rise; SpaceX, AMD Dive As Arista, Eli Lilly Jump With S&P 500 At Highs 8/04/2026 The Dow and S&P 500 hit new highs while the Nasdaq powered u...

Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop
Simply Wall St 3h
Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope

The race to treat obesity and metabolic disease is reshaping expectations across large pharmaceutical stocks, and Eli Lilly is front and center after its Q2 ear...

Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope
Seeking Alpha 4h
CVS Health expands GLP-1 offerings with Lilly

CVS Health (CVS) on Wednesday announced a collaboration with Eli Lilly (LLY) to allow patients to more easily access the Indiana-based drugmaker’s weight loss t...

CVS Health expands GLP-1 offerings with Lilly
The Wall Street Journal 4h
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand

For the year, Eli Lilly said it now expects adjusted earnings of $35.50 to $36.50 a share, lowering the high-end of its outlook by 50 cents. Michael Nagle / Blo...

Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
MarketWatch 5h
Lilly’s revenue soars 48%, driven by demand of its GLP-1s

Sales of Eli Lilly’s GLP-1 drugs like Mounjaro soared in the second quarter. Eli Lilly, the American drug giant, had another record-breaking quarter. The weig...

Lilly’s revenue soars 48%, driven by demand of its GLP-1s
TipRanks 5h
Eli Lilly reports Q2 EPS $8.38, consensus $6.58

Reports Q2 revenue $22.97B, consensus $20.69B. “Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance,” said David A....

Nasdaq 5h
Eli Lilly And Co. Bottom Line Advances In Q2

(RTTNews) - Eli Lilly And Co. (LLY) revealed a profit for its second quarter that Increases, from last year The company's bottom line came in at $7.095 billion...

Eli Lilly And Co. Bottom Line Advances In Q2

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.